Pubblicazioni

1. Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry. Big MS Data Network. Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700.

   Leggi l'articolo

2. Simone M, Lucisano G, Guerra T, et al. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis. J Neurol. 2024 Ago 23; 271(10):6782-6790. doi:10.1007/s00415-024-12638-0.

   Leggi l'articolo

3. Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, Foschi M, Patti F, Granella F, Romano S, Cavalla P, De Luca G, Gallo P, Bellantonio P, Gallo A, Montepietra S, Di Sapio A, Vianello M, Quatrale R, Spitaleri D, Clerici R, Torri Clerici V, Cocco E, Brescia Morra V, Marfia GA, Boccia VD, Filippi M, Amato MP, Trojano M; Italian MS Register. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. Ann Clin Transl Neurol. 2024 Jul 5. doi: 10.1002/acn3.52118.

   Leggi l'articolo

4. Portaccio E, Betti M, De Meo E, Addazio I, Pastò L, Razzolini L, Totaro R, Spitaleri D, Lugaresi A, Cocco E, Onofrj M, Di Palma F, Patti F, Maimone D, Valentino P, Torri Clerici V, Protti A, Ferraro D, Lus G, Maniscalco GT, Brescia Morra V, Salemi G, Granella F, Pesci I, Bergamaschi R, Aguglia U, Vianello M, Simone M, Lepore V, Iaffaldano P, Comi G, Filippi M, Trojano M, Amato MP Italian Multiple Sclerosis Register. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448-4.

   Leggi l'articolo

5. Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F; Italian MS Register Study Group. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study. Neurotherapeutics. 2024 May;21(4):e00363. doi: 10.1016/j.neurot.2024.e00363.

   Leggi l'articolo

6. Lepore V, Paletta P, Bosetti C, Santucci C, Ponzio M, Pupillo E, Leone MA, Bergamaschi R, Mosconi P, Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of the Italian Multiple Sclerosis and Related Disorders. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register. Mult Scler Relat Disord. 2024 Jul;87:105638. doi: 10.1016/j.msard.2024.105638.

   Leggi l'articolo

7. Glaser A, Butzkueven H, van der Walt A, Gray O, Spelman T, Zhu C, Trojano M, Iaffaldano P, Battaglia MA, Lucisano G, Vukusic S, Vukusic I, Casey R, Horakova D, Drahota J, Magyari M, Joensen H, Pontieri L, Elberling F, Klyve P, Mouresan EF, Forsberg L, Hillert J. Big Multiple Sclerosis Data network: an international registry research network. J Neurol. 2024 Jun;271(6):3616-3624. doi: 10.1007/s00415-024-12303-6.

   Leggi l'articolo

8. Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6.

   Leggi l'articolo

9. Lorefice L, Ferraro OE, Fenu G, Amato MP, Bresciamorra V, Conte A, De Luca G, Ferraro D, Filippi M, Gazzola P, Iaffaldano P, Inglese M, Lus G, Marfia GA, Patti F, Pesci I, Salemi G, Trojano M, Zaffaroni M, Monti MC, Cocco E; Italian MS Register. Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry. J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152-9. Online ahead of print. PMID: 38172380.

   Leggi l'articolo

10. Iaffaldano P, Lucisano G, Guerra T, Patti F, Cocco E, De Luca G, Brescia Morra V, Pozzilli C, Zaffaroni M, Ferraro D, Gasperini C, Salemi G, Bergamaschi R, Lus G, Inglese M, Romano S, Bellantonio P, Di Monte E, Maniscalco GT, Conte A, Lugaresi A, Vianello M, Torri Clerici VLA, Di Sapio A, Pesci I, Granella F, Totaro R, Marfia GA, Danni MC, Cavalla P, Valentino P, Aguglia U, Montepietra S, Ferraro E, Protti A, Spitaleri D, Avolio C, De Riz M, Maimone D, Cavaletti G, Gazzola P, Tedeschi G, Sessa M, Rovaris M, Di Palma F, Gatto M, Cargnelutti D, De Robertis F, Logullo FO, Rini A, Meucci G, Ardito B, Banfi P, Nasuelli D, Paolicelli D, Rocca MA, Portaccio E, Chisari CG, Fenu G, Onofrj M, Carotenuto A, Ruggieri S, Tortorella C, Ragonese P, Nica M, Amato MP, Filippi M, Trojano M; Italian MS Register. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry. J Neurol. 2024 Mar;271(3):1150-1159. doi: 10.1007/s00415-023-12137-8.

    Leggi l'articolo

11. Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP. Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Front Neurol. 2023 Dec;14:1274194. doi: 10.3389/fneur.2023.1274194.

    Leggi l'articolo

12. Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, Paolicelli D, Betti M, De Meo E, Pastò L, Razzolini L, Rocca MA, Ferrè L, Brescia Morra V, Patti F, Zaffaroni M, Gasperini C, De Luca G, Ferraro D, Granella F, Pozzilli C, Romano S, Gallo P, Bergamaschi R, Coniglio MG, Lus G, Vianello M, Banfi P, Lugaresi A, Totaro R, Spitaleri D, Cocco E, Di Palma F, Maimone D, Valentino P, Torri Clerici V, Protti A, Maniscalco GT, Salemi G, Pesci I, Aguglia U, Lepore V, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register. Multiple Sclerosis Progression and Relapse Activity in Children. JAMA Neurol. 2023 Nov 27:e234455. doi: 10.1001/jamaneurol.2023.4455. Online ahead of print. PMID: 38010712.

    Leggi l'articolo

13. Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A. OCREVID study group on behalf of the Italian MS Register.COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients. J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084-4. Online ahead of print.PMID: 37982852.

    Leggi l'articolo

14. Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY). Neurotherapeutics. 2023 Aug 23. doi: 10.1007/s13311-023-01415-y. Online ahead of print.

    Leggi l'articolo

15. Mosconi P, Guerra T, Paletta P, D'Ettorre A, Ponzio M, Battaglia MA, Amato MP, Bergamaschi R, Capobianco M, Comi G, Gasperini C, Patti F, Pugliatti M, Ulivelli M, Trojano M, Lepore V; Italian Multiple Sclerosis and Related Disorders Register Centres Group. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register. Neurol Sci. 2023 Nov;44(11):4001-4011. doi: 10.1007/s10072-023-06876-9. Epub 2023 Jun 14. PMID: 37311951.

    Leggi l'articolo

16. Zanghì A, Galgani S, Bellantonio P, Zaffaroni M, Borriello G, Inglese M, Romano S, Conte A, Patti F, Trojano M, Avolio C, D'Amico E; Italian MS Registry. Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotype. Eur J Neurol. 2023 Sep;30(9):2736-2744. doi: 10.1111/ene.15910. Epub 2023 Jun 29.

    Leggi l'articolo

17. Boffa G et al. Hematopoietic Stem Cell Transplantation In People With Active Secondary Progressive Multiple Sclerosis. Neurology. 2023 Mar 14;100(11):e1109-e1122. doi: 10.1212/WNL.0000000000206750. Epub 2022 Dec 21.

    Leggi l'articolo

18. Signori A, et al. Big MS Data Network. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry. 2022 Sep 28:jnnp-2022-329987. doi: 10.1136/jnnp-2022-329987.

    Leggi l'articolo

19. Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Brescia Morra V, Zaffaroni M, Pozzilli C, Cocco E, Sola P, Salemi G, Inglese M, Bergamaschi R, Gasperini C, Conte A, Salvetti M, Lus G, Maniscalco GT, Totaro R, Vianello M, Granella F, Ferraro E, Aguglia U, Gatto M, Sangalli F, Chisari CG, De Luca G, Carotenuto A, Baroncini D, Colombo D, Nica M, Paolicelli D, Comi G, Filippi M, Amato MP, Trojano M. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. Mult Scler. 2022 Dec;28(14):2243-2252. doi: 10.1177/13524585221114007. Epub 2022 Aug 15.PMID: 35971322.

    Leggi l'articolo

20. Portaccio E, Bellinvia A, Fonderico M, Pastò L, Razzolini L, Totaro R, Spitaleri D, Lugaresi A, Cocco E, Onofrj M, Di Palma F, Patti F, Maimone D, Valentino P, Confalonieri P, Protti A, Sola P, Lus G, Maniscalco GT, Brescia Morra V, Salemi G, Granella F, Pesci I, Bergamaschi R, Aguglia U, Vianello M, Simone M, Lepore V, Iaffaldano P, Filippi M, Trojano M, Amato MP. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain. 2022 Aug 27;145(8):2796-2805. doi: 10.1093/brain/awac111.

    Leggi l'articolo

21. Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. PMID: 35877104 Clinical Trial.

    Leggi l'articolo

22. Bergamaschi R, Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Mosconi P; Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of Italian SM and Related Disorders Register. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurol Sci. 2022 Sep;43(9):5459-5469. doi: 10.1007/s10072-022-06169-7. Epub 2022 Jun 7. PMID: 35672479.

    Leggi l'articolo

23. De Meo E, Filippi M, Trojano M, Comi G, Patti F, Brescia Morra V, Salemi G, Onofrj M, Lus G, Cocco E, Fonderico M, Torri Clerici V, Maniscalco GT, Valentino P, Bertolotto A, Lugaresi A, Bergamaschi R, Rovaris M, Sola P, Tedeschi G, Pesci I, Aguglia U, Cavalla P, Maimone D, Granella F, Vianello M, Simone M, Portaccio E, Amato MP. Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis. Ann Neurol. 2022 Apr;91(4):483-495. doi: 10.1002/ana.26322. Epub 2022 Feb 28. PMID: 35150168.

    Leggi l'articolo

24. Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M; Italian MS Register. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):e1141. doi: 10.1212/NXI.0000000000001141.

    Leggi l'articolo

25. Zanghì A, Avolio C, Amato MP, et al. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register [published online ahead of print, 2022 Jan 2]. Mult Scler Relat Disord. 2022;58:103489. doi:10.1016/j.msard.2022.103489.

    Leggi l'articolo

26. Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, D'Amico E; Italian MS register. First-line therapies in late-onset multiple sclerosis: An Italian MS registry study. Eur J Neurol. 2021 Dec;28(12):4117-4123. doi: 10.1111/ene.15006.

    Leggi l'articolo

27. Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M. Italian MS Register. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. J Neurol. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Online ahead of print.PMID: 34292396.

    Leggi l'articolo

28. Zanghì, A, Avolio, C, Amato, MP, et al. First-line therapies in late-onset multiple sclerosis: An Italian registry study. Eur J Neurol. 2021; 28: 4117– 4123. https://doi.org/10.1111/ene.15006.

    Leggi l'articolo

29. Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28. PMID: 34181077.

    Leggi l'articolo

30. Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M; Italian MS Register. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021 May 31;14:17562864211019574. doi: 10.1177/17562864211019574. eCollection 2021. PMID: 34104220 .

    Leggi l'articolo

31. Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A; Italian MS registry. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021 Jun 1;78(6):726-735. doi: 10.1001/jamaneurol.2021.1008. PMID: 33938921.

    Leggi l'articolo

32. Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021 Sep;27(10):1543-1555. doi: 10.1177/13524585211010128.

    Leggi l'articolo

33. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021 Mar 17;12:647811. doi: 10.3389/fneur.2021.647811.

    Leggi l'articolo

34. D'Amico E, Zanghì A, Romeo M, et al. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics. 2021;18(2):905-919. doi:10.1007/s13311-020-01001-6.

    Leggi l'articolo

35. Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi G, Filippi M, Amato MP, Trojano M; Italian MS Register. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366.

    Leggi l'articolo

36. Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. PMID: 33058344.

    Leggi l'articolo

37. Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, Sparaco M, Rovaris M, D'Arma A, Lugaresi A, Ferrò MT, Grossi P, Di Sapio A, Cocco E, Granella F, Curti E, Lepore V, Trojano M, Patti F; Italian MS Register Study Group. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1297-1303. doi: 10.1136/jnnp-2020-323472. Epub 2020 Oct 14.PMID: 33055141.

    Leggi l'articolo

38. Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. PMID: 32935843.

    Leggi l'articolo

39. Patti F, Visconti A, Capacchione A, Roy S, Trojano M; CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685. doi: 10.1177/1756286420922685. eCollection 2020.

    Leggi l'articolo

40. Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. J Neurol. 2019 Dec;266(12):3098-3107. doi: 10.1007/s00415-019-09531-6. Epub 2019 Sep 18. PMID: 31535270.

    Leggi l'articolo

41. Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group. The Italian multiple sclerosis register. Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. PMID: 30426289 .

    Leggi l'articolo

42. Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

    Leggi l'articolo

43. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260.

    Leggi l'articolo

44. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci. 2009 Nov;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036.

    Leggi l'articolo

45. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757.

    Leggi l'articolo

• RESEARCH PROJECTS OF THE ITALIAN SM REGISTER

• Anno 2022

  Research Projects of the Italian SM Register (RISM): Presentation of the Research Projects based on the RISM data.

  Download the Research Projects book presented ad Ectrim 2022

• Anno 2019

  Data from the Italian Multiple Sclerosis Registry are useful to promote the equity of access to care by comparing the welfare practices at national and local level. Data collected through the Italian Multiple Sclerosis Registry are used also for strategic research projects according with the priorities identified. Currently 21 Projects are active on the three main areas of the strategic research line: 6 descriptive epidemiology projects, 13 projects on the optimization of the therapy and 2 projects on rare forms of the disease.
  Download the Research Projects book presented ad Ectrim 2019

  Download Articolo

Riunione dei centri partecipanti al progetto Registro Italiano SM&PC - 11 novembre 2024

Riunione dei centri partecipanti al progetto Registro Italiano SM - 28 novembre 2020